767 related articles for article (PubMed ID: 34387604)
41. Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075).
Ramos JC; Sparano JA; Rudek MA; Moore PC; Cesarman E; Reid EG; Henry D; Ratner L; Aboulafia D; Lee JY; Ambinder RF; Mitsuyasu R; Noy A
Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):180-190.e2. PubMed ID: 29426719
[TBL] [Abstract][Full Text] [Related]
42. Multiple cytokine-producing aggressive EBV-positive diffuse large B cell lymphoma, not otherwise specified with hemophagocytic syndrome.
Nakayama S; Morita Y; Espinoza JL; Rai S; Taniguchi Y; Taniguchi T; Miyake Y; Tanaka H; Ashida T; Matsumura I
Ann Hematol; 2020 Feb; 99(2):381-383. PubMed ID: 31768673
[No Abstract] [Full Text] [Related]
43. Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial.
Kimani S; Painschab MS; Kaimila B; Kasonkanji E; Zuze T; Tomoka T; Mulenga M; Nyasosela R; Chikasema M; Mtangwanika A; Chawinga M; Mhango W; Nicholas S; Chimzimu F; Kampani C; Krysiak R; Lilly A; Randall C; Seguin R; Westmoreland KD; Montgomery ND; Fedoriw Y; Gopal S
Lancet Glob Health; 2021 Jul; 9(7):e1008-e1016. PubMed ID: 34022150
[TBL] [Abstract][Full Text] [Related]
44. Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy.
Suzuki T; Maruyama D; Miyagi-Maeshima A; Nomoto J; Tajima K; Ito Y; Hatta S; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Taniguchi H; Izutsu K; Kobayashi Y; Tobinai K
Cancer Med; 2021 Aug; 10(15):5101-5109. PubMed ID: 34105893
[TBL] [Abstract][Full Text] [Related]
45. CD56-positive diffuse large B-cell lymphoma/leukemia with
Liu Y; Shen J; Awal Issah M; Liu T; Zhou H; Fu H
J Int Med Res; 2020 May; 48(5):300060520918087. PubMed ID: 32363958
[TBL] [Abstract][Full Text] [Related]
46. Immunotherapy with cells.
Chong EA; Porter DL
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):590-597. PubMed ID: 33275723
[TBL] [Abstract][Full Text] [Related]
47. Dual Threat of Epstein-Barr Virus: an Autopsy Case Report of HIV-Positive Plasmablastic Lymphoma Complicating EBV-Associated Hemophagocytic Lymphohistiocytosis.
Koizumi Y; Imadome KI; Ota Y; Minamiguchi H; Kodama Y; Watanabe D; Mikamo H; Uehira T; Okada S; Shirasaka T
J Clin Immunol; 2018 May; 38(4):478-483. PubMed ID: 29687211
[TBL] [Abstract][Full Text] [Related]
48. Real-world efficacy of DA-EPOCH-R/HD-MTX regimen in CD5-positive diffuse large B cell lymphoma: a single-institute analysis.
Toyama K; Nakayama K; Terasaki S; Matsumura I; Kanaya S; Iino H; Noguchi H; Tahara K; Yoshida T; Saito A
J Clin Exp Hematop; 2023; 63(1):19-24. PubMed ID: 36990773
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti-CD19-chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B-cell lymphoma and high tumor burden.
Mu J; Deng H; Lyu C; Yuan J; Li Q; Wang J; Jiang Y; Deng Q; Shen J
Hematol Oncol; 2023 Apr; 41(2):275-284. PubMed ID: 35195933
[TBL] [Abstract][Full Text] [Related]
50. Endoscopic appearance of AIDS-related gastrointestinal lymphoma with c-MYC rearrangements: case report and literature review.
Tanaka S; Nagata N; Mine S; Igari T; Kobayashi T; Sugihara J; Honda H; Teruya K; Kikuchi Y; Oka S; Uemura N
World J Gastroenterol; 2013 Aug; 19(29):4827-31. PubMed ID: 23922484
[TBL] [Abstract][Full Text] [Related]
51. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
52. Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up.
Zhou H; Xu-Monette ZY; Xiao L; Strati P; Hagemeister FB; He Y; Chen H; Li Y; Manyam GC; Li Y; Montes-Moreno S; Piris MA; Young KH
Blood Cancer J; 2020 May; 10(5):49. PubMed ID: 32366834
[TBL] [Abstract][Full Text] [Related]
53. [Epstein-Barr virus-positive diffuse large B-cell lymphoma following peripheral T-cell lymphoma, not otherwise specified: report of a case].
Zhang F; Liu YH; Zhuang HG; Li L; Luo XL; Xu J
Zhonghua Bing Li Xue Za Zhi; 2010 Jun; 39(6):414-5. PubMed ID: 21055162
[No Abstract] [Full Text] [Related]
54. Leukocytoclastic vasculitis as early manifestation of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly.
Zoroquiain P; González S; Molgó M; Rodríguez A; Valbuena JR
Am J Dermatopathol; 2012 May; 34(3):330-4. PubMed ID: 22197862
[TBL] [Abstract][Full Text] [Related]
55. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
56. CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma: physician preferences trading off benefits, risks and time to infusion.
Boeri M; Purdum AG; Sutphin J; Hauber B; Kaye JA
Future Oncol; 2021 Dec; 17(34):4697-4709. PubMed ID: 34581197
[TBL] [Abstract][Full Text] [Related]
57. Epstein-Barr virus-negative diffuse large B-cell lymphoma hosts intra- and peritumoral B-cells with activated Epstein-Barr virus.
Stuhlmann-Laeisz C; Szczepanowski M; Borchert A; Brüggemann M; Klapper W
Virchows Arch; 2015 Jan; 466(1):85-92. PubMed ID: 25339301
[TBL] [Abstract][Full Text] [Related]
58. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma.
Castillo JJ; Reagan JL; Sikov WM; Winer ES
Br J Haematol; 2015 May; 169(3):352-5. PubMed ID: 25612847
[TBL] [Abstract][Full Text] [Related]
59. Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study.
García-Suárez J; Bañas H; Arribas I; De Miguel D; Pascual T; Burgaleta C
Br J Haematol; 2007 Jan; 136(2):276-85. PubMed ID: 17233819
[TBL] [Abstract][Full Text] [Related]
60. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
Wang J; Wang Y; Wu L; Zhang J; Lai W; Wang Z
J Hematol Oncol; 2016 Sep; 9(1):84. PubMed ID: 27613189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
